Stock MAGLE MAGLE CHEMOSWED HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Magle Chemoswed Holding AB

Equities

MAGLE

SE0014401014

Market Closed - Nasdaq Stockholm
Other stock markets
 16:13:42 15/05/2024 BST 		5-day change 1st Jan Change
32.4 SEK 0.00% Intraday chart for Magle Chemoswed Holding AB +1.25% +28.57%
04-18 Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-22 Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MAGLE CHEMOSWED HOLDING AB Stock Magle Chemoswed Holding AB
+28.57% 32.34M -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
B+
NOVARTIS AG Stock Novartis AG
+9.93% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
A+
AMGEN INC. Stock Amgen Inc.
+10.77% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.10% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. MAGLE Stock
  4. Ratings Magle Chemoswed Holding AB